Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA)\nand may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal\natrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of\na new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA\nwere divided into two groups: patients with a known intolerance to iron sulfate were treated with\nsucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time\nwere assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females,\nmean age 49 �± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels\ncompared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a\nsignificant improvement in all iron parameters, with no statistical difference between the two groups.\nPatients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as\nabdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general\nwell-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective\nin providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA,\nand known intolerance to iron sulfate.
Loading....